CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday

Key Points

• CeriBell (CBLL) is set to announce its Q2 2025 earnings on August 5th, with expected earnings of ($0.40) per share and revenue of $20.52 million.
• Insider selling has occurred recently, with Director Rebecca B. Robertson and CEO Xingjuan Chao reducing their stakes, indicating potential concerns about stock performance.
• Currently, CeriBell holds a consensus "Buy" rating from analysts, with a target price around $32.14.

CeriBell (NASDAQ:CBLL - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $20.52 million for the quarter. CeriBell has set its FY 2025 guidance at EPS.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Stock Down 0.6%

CBLL traded down $0.08 on Friday, hitting $14.32. 26,871 shares of the company's stock were exchanged, compared to its average volume of 276,779. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The company has a current ratio of 17.36, a quick ratio of 16.81 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average price of $17.07 and a 200-day moving average price of $18.82.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CBLL shares. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. BTIG Research started coverage on shares of CeriBell in a research report on Tuesday, June 24th. They set a "buy" rating and a $30.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $32.14.

Insider Activity

In related news, Director Rebecca B. Robertson sold 20,000 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $17.14, for a total value of $342,800.00. Following the sale, the director directly owned 28,675 shares in the company, valued at approximately $491,489.50. The trade was a 41.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Xingjuan Chao sold 25,000 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.00, for a total transaction of $425,000.00. Following the completion of the sale, the chief executive officer owned 776,022 shares in the company, valued at approximately $13,192,374. This trade represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 113,633 shares of company stock worth $1,965,261. Corporate insiders own 20.10% of the company's stock.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.